{
  "trial_id": "NCT02737501",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG performance status, stage of NSCLC, ALK rearrangement status, prior anticancer therapy, organ function, QT interval, pregnancy status, use of contraception, presence of CNS metastases, history of cardiovascular disease, history of hypertension, history of pulmonary interstitial disease, history of infections, history of HIV infection, hypersensitivity to study drugs, gastrointestinal conditions.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "Race/Ethnicity",
        "Region of Enrollment",
        "Global Health Status/Quality of Life (QoL)"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "stage of NSCLC",
        "ALK rearrangement status",
        "prior anticancer therapy",
        "organ function",
        "QT interval",
        "pregnancy status",
        "use of contraception",
        "presence of CNS metastases",
        "history of cardiovascular disease",
        "history of hypertension",
        "history of pulmonary interstitial disease",
        "history of infections",
        "history of HIV infection",
        "hypersensitivity to study drugs",
        "gastrointestinal conditions"
      ]
    },
    "processed-gen-response": "Age, gender, ECOG performance status, stage of NSCLC, ALK rearrangement status, prior anticancer therapy, organ function, QT interval, pregnancy status, use of contraception, presence of CNS metastases, history of cardiovascular disease, history of hypertension, history of pulmonary interstitial disease, history of infections, history of HIV infection, hypersensitivity to study drugs, gastrointestinal conditions."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, ALK rearrangement status, Tumor stage, Measurable lesion status, Organ function parameters, QT interval, Prior anticancer therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Global Health Status/Quality of Life (QoL)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "ALK rearrangement status",
        "Tumor stage",
        "Measurable lesion status",
        "Organ function parameters",
        "QT interval",
        "Prior anticancer therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, ALK rearrangement status, Tumor stage, Measurable lesion status, Organ function parameters, QT interval, Prior anticancer therapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, ALK Rearrangement Status, Number of Prior Systemic Anticancer Therapies, Presence of Brain Metastases, Presence of Liver Metastases, Presence of Bone Metastases, Best Overall Response to Prior Systemic Anticancer Therapy, Time Since Initial Diagnosis of NSCLC, Time Since Diagnosis of Advanced or Metastatic NSCLC.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Global Health Status/Quality of Life (QoL)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "ALK Rearrangement Status",
        "Number of Prior Systemic Anticancer Therapies",
        "Presence of Brain Metastases",
        "Presence of Liver Metastases",
        "Presence of Bone Metastases",
        "Best Overall Response to Prior Systemic Anticancer Therapy",
        "Time Since Initial Diagnosis of NSCLC",
        "Time Since Diagnosis of Advanced or Metastatic NSCLC"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, ALK Rearrangement Status, Number of Prior Systemic Anticancer Therapies, Presence of Brain Metastases, Presence of Liver Metastases, Presence of Bone Metastases, Best Overall Response to Prior Systemic Anticancer Therapy, Time Since Initial Diagnosis of NSCLC, Time Since Diagnosis of Advanced or Metastatic NSCLC."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, smoking history, histology, ALK rearrangement status, number and location of metastatic sites, prior systemic anticancer therapy, prior radiation therapy, QTcF interval, creatinine clearance, liver function tests, complete blood counts, body mass index (BMI), tumor size and location.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Race/Ethnicity",
          "ethnicity"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "QTcF interval",
          "QTcF interval"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Global Health Status/Quality of Life (QoL)"
      ],
      "remaining_candidate_features": [
        "smoking history",
        "histology",
        "ALK rearrangement status",
        "number and location of metastatic sites",
        "prior systemic anticancer therapy",
        "prior radiation therapy",
        "creatinine clearance",
        "liver function tests",
        "complete blood counts",
        "body mass index (BMI)",
        "tumor size and location"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, ECOG performance status, smoking history, histology, ALK rearrangement status, number and location of metastatic sites, prior systemic anticancer therapy, prior radiation therapy, QTcF interval, creatinine clearance, liver function tests, complete blood counts, body mass index (BMI), tumor size and location."
  }
}